USP22 and cancer: To determine the clinical implications of USP22 copy number losses, TCGA data from 19 distinct cancer types were interrogated and it was determined that USP22 is more frequently lost than gained in the majority (17/19) of cancers and that USP22 copy number losses correspond with worse progression-free survival.